Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes with luspatercept in patients with β-thalassemia: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

NBNihal BabikerWRWania Ur RehamnHAHind El Azzazi

Discussion

Loading...

Member takes

Overview

Systematic review and meta-analysis shows luspatercept improves transfusion independence and raises safety concerns in patients with β-thalassemia, highlighting adverse events and potential benefits.

Key Points

  • Luspatercept significantly decreases the transfusion burden in patients, improving their overall quality of life, and providing new therapeutic options.
  • Adverse events reported include grade 3 complications, with a moderate incidence of nausea among patients undergoing treatment.
  • Meta-analysis pooled data from four studies, encompassing findings from 447 patients across two Phase II and one Phase III trials.
  • The systematic review underscores the emerging role of luspatercept in managing β-thalassemia, advocating for further exploration in clinical settings.

Cite This Study

Babiker et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2f9https://doi.org/10.1182/blood-2025-7961
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes with luspatercept in patients with β-thalassemia: a systematic review and meta-analysis2026
  2. 2Luspatercept in β-thalassemia: Meta-analysis of efficacy and safety across transfusion-dependent and non-transfusion-dependent populations2025
  3. 3Efficacy of luspatercept in reducing transfusion burden and its impact on liver iron concentration in beta-thalassemia major: A systematic review and meta-analysis2025
  4. 4A clinical study on the Efficacy and safety of luspatercept in Chinese patients with non-transfusion-dependent β-thalassemia2025
  5. 5Transfusion independence in thalassemia patients after failure of gene therapy or with hemoglobin h constant spring and hb e using luspatercept: A case series2025